Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 22;11(6):e121402.
doi: 10.5812/aapm.121402. eCollection 2021 Dec.

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence

Eric Y Chen  1 , Sascha S Beutler  1 , Alan D Kaye  2 , Amber N Edinoff  3 , Seyed-Hossein Khademi  4 , Andrea E Stoltz  5 , Nicole R Rueb  5 , Elyse M Cornett  2 , Winston J Suh  2
Affiliations
Review

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence

Eric Y Chen et al. Anesth Pain Med. .

Abstract

Neuropathic pain is a challenge for physicians to treat and often requires a multimodal approach with both pharmacologic and lifestyle interventions. Mirogabalin, a potent, selective ligand of the α2δ-1 and α2δ-2 subunits of voltage-gated calcium channels (VGCCs), provides analgesia by inhibiting neurotransmitter release at the presynaptic end of the neuron. Mirogabalin offers more sustained analgesia than its gabapentinoid counterparts in addition to a wider safety margin for adverse events. Recent clinical trials of mirogabalin have demonstrated both efficacy and tolerability of the drug for the treatment of diabetic peripheral neuropathic pain and postherpetic neuralgia, leading to its approval in Japan. While still not yet FDA approved, mirogabalin is still in its infancy and offers potential into the treatment of neuropathic pain and its associated comorbidities.

Keywords: Anxiety; Diabetic Peripheral Neuropathic Pain; Fibromyalgia; Mirogabalin, Gabapentinoid; Postherpetic Neuralgia.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests: Authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.. Chemical structure of mirogabalin.
See this image and copyright information in PMC

References

    1. Deeks ED. Mirogabalin: First Global Approval. Drugs. 2019;79(4):463–8. doi: 10.1007/s40265-019-01070-8. - DOI - PubMed
    1. Kim JY, Abdi S, Huh B, Kim KH. Mirogabalin: could it be the next generation gabapentin or pregabalin? Korean J Pain. 2021;34(1):4–18. doi: 10.3344/kjp.2021.34.1.4. - DOI - PMC - PubMed
    1. Burgess J, Javed S, Frank B, Malik RA, Alam U. Mirogabalin besylate in the treatment of neuropathic pain. Drugs Today (Barc). 2020;56(2):135–49. doi: 10.1358/dot.2020.56.2.3100504. - DOI - PubMed
    1. Tetsunaga T, Tetsunaga T, Nishida K, Misawa H, Takigawa T, Yamane K, et al. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study. J Orthop Surg Res. 2020;15(1):191. doi: 10.1186/s13018-020-01709-3. - DOI - PMC - PubMed
    1. Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother. 2016;16(11):1263–77. doi: 10.1080/14737175.2016.1202764. - DOI - PubMed

LinkOut - more resources